NO995006L - Nye forbindelser - Google Patents

Nye forbindelser

Info

Publication number
NO995006L
NO995006L NO995006A NO995006A NO995006L NO 995006 L NO995006 L NO 995006L NO 995006 A NO995006 A NO 995006A NO 995006 A NO995006 A NO 995006A NO 995006 L NO995006 L NO 995006L
Authority
NO
Norway
Prior art keywords
new connections
compounds
processes
formula
preparation
Prior art date
Application number
NO995006A
Other languages
English (en)
Other versions
NO995006D0 (no
Inventor
David Cheshire
Martin Cooper
David Donald
Philip Thorne
Original Assignee
Astra Pharma Prod
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Pharma Prod filed Critical Astra Pharma Prod
Publication of NO995006L publication Critical patent/NO995006L/no
Publication of NO995006D0 publication Critical patent/NO995006D0/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Use Of Switch Circuits For Exchanges And Methods Of Control Of Multiplex Exchanges (AREA)

Abstract

Farmasøytisk nyttige pyra2o]o[3,4-d]pyrimidindionforbindelser av formel (I) w / N-R (D fremgangsmåter for deres fremstilling, farmasøytiske preparater inneholdende slike forbindelser, og deres anvendelse for behandling av forskjellige sykdommer.
NO995006A 1997-04-15 1999-10-14 Nye forbindelser NO995006D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9701398A SE9701398D0 (sv) 1997-04-15 1997-04-15 Novel compounds
PCT/SE1998/000640 WO1998046606A1 (en) 1997-04-15 1998-04-07 Novel compounds

Publications (2)

Publication Number Publication Date
NO995006L true NO995006L (no) 1999-10-14
NO995006D0 NO995006D0 (no) 1999-10-14

Family

ID=20406576

Family Applications (1)

Application Number Title Priority Date Filing Date
NO995006A NO995006D0 (no) 1997-04-15 1999-10-14 Nye forbindelser

Country Status (21)

Country Link
US (1) US6028074A (no)
EP (1) EP0975636B1 (no)
JP (1) JP2001520645A (no)
KR (1) KR20010006350A (no)
CN (1) CN1259951A (no)
AT (1) ATE245648T1 (no)
AU (1) AU733066B2 (no)
BR (1) BR9808540A (no)
CA (1) CA2286078A1 (no)
DE (1) DE69816608T2 (no)
EE (1) EE9900465A (no)
HU (1) HUP0002104A3 (no)
ID (1) ID22746A (no)
IL (1) IL132153A0 (no)
IS (1) IS5198A (no)
NO (1) NO995006D0 (no)
PL (1) PL336230A1 (no)
SE (1) SE9701398D0 (no)
SK (1) SK135699A3 (no)
TR (1) TR199902538T2 (no)
WO (1) WO1998046606A1 (no)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9801399D0 (sv) 1998-04-21 1998-04-21 Astra Pharma Prod Method and apparatus for filling containers
GC0000177A (en) * 1998-12-17 2006-03-29 Smithkline Beecham Thrombopoietin mimetics
CY2010012I2 (el) 2000-05-25 2020-05-29 Novartis Ag Μιμητικα θρομβοποιητινης
JP2004527541A (ja) 2001-03-01 2004-09-09 スミスクライン・ビーチャム・コーポレイション トロンボポエチン模倣物
WO2003020702A2 (en) 2001-08-31 2003-03-13 The Rockefeller University Phosphodiesterase activity and regulation of phosphodiesterase 1-b-mediated signaling in brain
AR040083A1 (es) 2002-05-22 2005-03-16 Smithkline Beecham Corp Compuesto bis-(monoetanolamina) del acido 3'-[(2z)-[1-(3,4-dimetilfenil) -1,5-dihidro-3-metil-5-oxo-4h-pirazol-4-iliden] hidrazino] -2'-hidroxi-[1,1'-bifenil]-3-carboxilico, procedimiento para prepararlo, composicion farmaceutica que lo comprende, procedimiento para preparar dicha composicion farmac
TW200526638A (en) 2003-10-22 2005-08-16 Smithkline Beecham Corp 2-(3,4-dimethylphenyl)-4-{[2-hydroxy-3'-(1H-tetrazol-5-yl)biphenyl-3-yl]-hydrazono}-5-methyl-2,4-dihydropyrazol-3-one choline
US9226885B2 (en) * 2005-05-24 2016-01-05 Allium Vitalis Incorporated Personal care and medicinal products incorporating bound organosulfur groups
WO2006133261A2 (en) 2005-06-06 2006-12-14 Intra-Cellular Therapies, Inc. Organic compounds
JP5453086B2 (ja) * 2006-06-06 2014-03-26 イントラ−セルラー・セラピーズ・インコーポレイテッド 有機化合物
US9198924B2 (en) 2006-11-13 2015-12-01 Intra-Cellular Therapies, Inc. Organic compounds
EP2089034A4 (en) 2006-12-05 2010-07-28 Intra Cellular Therapies Inc NEW USES
ECSP077628A (es) 2007-05-03 2008-12-30 Smithkline Beechman Corp Nueva composición farmacéutica
WO2009073210A1 (en) * 2007-12-06 2009-06-11 Intra-Cellular Therapies, Inc Organic compounds
CN104370920A (zh) 2007-12-06 2015-02-25 武田药品工业株式会社 有机化合物
WO2010065148A1 (en) 2008-12-06 2010-06-10 Intra-Cellular Therapies, Inc. Organic compounds
BRPI0922700A2 (pt) 2008-12-06 2015-08-11 Intracellular Therapies Inc Compostos orgânicos
MX2011005935A (es) 2008-12-06 2011-12-16 Intra Cellular Therapies Inc Compuestos organicos.
EA201170772A1 (ru) * 2008-12-06 2012-03-30 Интра-Селлулар Терапиз, Инк. Органические соединения
JP5778582B2 (ja) 2008-12-06 2015-09-16 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 有機化合物
EA201170771A1 (ru) 2008-12-06 2012-01-30 Интра-Селлулар Терапиз, Инк. Органические соединения
EP2400970A4 (en) 2009-02-25 2012-07-18 Intra Cellular Therapies Inc PDE-1-HEMMER FOR EYE DRESSING
EA023857B1 (ru) * 2009-03-23 2016-07-29 Гленмарк Фармасеутикалс С.А. Сочлененные производные пиримидиндионов в качестве модуляторов trpa1
SG174398A1 (en) 2009-03-23 2011-10-28 Glenmark Pharmaceuticals Sa Furopyrimidinedione derivatives as trpa1 modulators
US8623880B2 (en) 2009-03-23 2014-01-07 Glenmark Pharmaceuticals S.A. Fused pyrimidine-dione derivatives as TRPA1 modulators
BRPI1009372A2 (pt) 2009-03-23 2016-05-31 Glenmark Pharmaceuticals Sa compostos, composição farmacêutica e respectivos usos
US9468637B2 (en) 2009-05-13 2016-10-18 Intra-Cellular Therapies, Inc. Organic compounds
SG176088A1 (en) 2009-05-29 2011-12-29 Glaxosmithkline Llc Methods of administration of thrombopoietin agonist compounds
JP6166534B2 (ja) 2009-08-05 2017-07-19 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 新規調節タンパク質および阻害剤
US9434730B2 (en) 2010-05-31 2016-09-06 Intra-Cellular Therapies, Inc. PDE1 inhibitor compounds
US9371327B2 (en) 2010-05-31 2016-06-21 Intra-Cellular Therapies, Inc. PDE1 inhibitor compounds
US9763948B2 (en) 2010-05-31 2017-09-19 Intra-Cellular Therapies, Inc. PDE1 inhibitory compounds and methods
TW201206937A (en) 2010-05-31 2012-02-16 Intra Cellular Therapies Inc Organic compounds
WO2012171016A1 (en) 2011-06-10 2012-12-13 Intra-Cellular Therapies, Inc. Organic compounds
KR20150015488A (ko) 2012-06-08 2015-02-10 그렌마크 파머수티칼스 에스. 아. 2-아미노-4-아릴티아졸 화합물의 아미드 및 그의 염
WO2014127331A1 (en) 2013-02-17 2014-08-21 Intra-Cellular Therapies, Inc. Novel uses
US9598426B2 (en) 2013-03-15 2017-03-21 Intra-Cellular Therapies, Inc. Organic compounds
US9545406B2 (en) 2013-03-15 2017-01-17 Intra-Cellular Therapies, Inc. Method of treating a CNS injury with a PDE1 inhibitor
EP3091983B1 (en) 2014-01-08 2019-10-02 Intra-Cellular Therapies, Inc. Pharmaceutical compositions comprising a pde-1 inhibitor and a pde-2 inhibitor
US9884872B2 (en) 2014-06-20 2018-02-06 Intra-Cellular Therapies, Inc. Organic compounds
DK3177627T3 (da) 2014-08-07 2019-10-21 Intra Cellular Therapies Inc Imidazo[1,2-a]-pyrazolo[4,3-e]-pyrimidin-4-on-derivater med pde1-hæmmende aktivitet
US9546175B2 (en) 2014-08-07 2017-01-17 Intra-Cellular Therapies, Inc. Organic compounds
US10285992B2 (en) 2014-08-07 2019-05-14 Intra-Cellular Therapies, Inc. Combinations of PDE1 inhibitors and NEP inhibitors and associated methods
IL292225B2 (en) 2014-09-17 2024-12-01 Intra Cellular Therapies Inc Derivatives of 5,7,7-trimethyl-[2H]-imidazo-[1,2-a]pyrazolo[4,3-e]pyrimidin-4(5H)-one and pharmaceutical compositions comprising them.
AU2015357498B2 (en) 2014-12-06 2019-09-12 Intra-Cellular Therapies, Inc. Organic compounds
US10300064B2 (en) 2014-12-06 2019-05-28 Intra-Cellular Therapies, Inc. Organic compounds
US10682354B2 (en) 2016-03-28 2020-06-16 Intra-Cellular Therapies, Inc. Compositions and methods
EP3475281A1 (en) * 2016-06-23 2019-05-01 H. Hoffnabb-La Roche Ag Novel [1,2,31triazolo[4,5-d]pyrimidine derivatives
EP3970719A1 (en) 2016-09-12 2022-03-23 Intra-Cellular Therapies, Inc. Pde1 inhibitor for use in a method of treatment or prophylaxis of inflammation and/or an inflammatory disease or disorder
JP7401442B2 (ja) 2018-01-31 2023-12-19 イントラ－セルラー・セラピーズ・インコーポレイテッド 新規使用
EP4025202A4 (en) 2019-09-03 2023-08-02 Intra-Cellular Therapies, Inc. NOVEL CONNECTIONS
US12364695B2 (en) 2020-06-02 2025-07-22 Intra-Cellular Therapies, Inc. Methods of treating inflammatory disease

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58500966A (ja) * 1981-04-22 1983-06-09 ビイク　グルデン　ロンベルク　ヒエ−ミツシエ　フアブリ−ク　ゲゼルシヤフト　ミツト　ベシユレンクテル　ハフツング 新規ピラゾロ〔３，４−ｄ〕ピリミジン、その製法及びこれを含有する医薬品
US4603203A (en) * 1983-12-14 1986-07-29 Takeda Chemical Industries, Ltd. 3-aminopyrazolo[3,4-d]pyrimidine derivatives and production thereof
EP0237289A3 (en) * 1986-03-14 1988-07-27 Takeda Chemical Industries, Ltd. Pyrazolo [3,4-d] pyrimidine derivatives, their production and use
US5712303A (en) * 1992-12-17 1998-01-27 Pfizer Inc. Pyrazoles and pyrazolopyrimidines having CRF antagonistic activity
TW444018B (en) * 1992-12-17 2001-07-01 Pfizer Pyrazolopyrimidines

Also Published As

Publication number Publication date
EE9900465A (et) 2000-04-17
EP0975636B1 (en) 2003-07-23
AU733066B2 (en) 2001-05-03
EP0975636A1 (en) 2000-02-02
WO1998046606A1 (en) 1998-10-22
AU7090998A (en) 1998-11-11
PL336230A1 (en) 2000-06-19
ID22746A (id) 1999-12-09
IS5198A (is) 1999-09-27
DE69816608D1 (de) 2003-08-28
ATE245648T1 (de) 2003-08-15
HUP0002104A2 (hu) 2001-01-29
NO995006D0 (no) 1999-10-14
SK135699A3 (en) 2000-05-16
CN1259951A (zh) 2000-07-12
IL132153A0 (en) 2001-03-19
JP2001520645A (ja) 2001-10-30
CA2286078A1 (en) 1998-10-22
HUP0002104A3 (en) 2002-03-28
US6028074A (en) 2000-02-22
TR199902538T2 (xx) 2000-02-21
KR20010006350A (ko) 2001-01-26
BR9808540A (pt) 2000-05-23
SE9701398D0 (sv) 1997-04-15
DE69816608T2 (de) 2004-04-15

Similar Documents

Publication Publication Date Title
NO20000311L (no) Nye forbindelser
NO20000313L (no) Nye forbindelser
NO995006D0 (no) Nye forbindelser
NO993027L (no) Pyrrolo[3,4-D]pyrimidinonderivater og deres anvendelse som legemidler
CA2272705A1 (en) Fused bicyclic pyrimidine derivatives
SE9702001D0 (sv) Novel compounds
NO20030381L (no) Bicyklopyrazoler som er aktive som kinaseinhibitorer, fremgangsmåte for deres fremstilling og farmasöytiske preparater som inneholder slikeforbindelser
GR3023825T3 (en) Benzopyran derivatives, processes for their preparation and their use and preparations containing the compounds
CA2263561A1 (en) Thienopyrimidines
TR199800012T1 (xx) Piroloprimidinler ve preparasyon i�in tatbikler.
NO20002788D0 (no) Nye forbindelser
AP9901435A0 (en) Bicycle heteroaromatic compounds as protein tyrosine kinase inhibitors.
CA2216535A1 (en) Protein kinase c inhibitors
NO904694D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive imidazolderivater.
CA2181175A1 (en) Dihydro Pyrazolopyrroles
NO901684D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive 3-substituerte-2-oksindol-derivater.
NO903088L (no) Fremgangsmaate for fremstilling av terapeutisk aktive diazepin-derivater.
MX9702382A (es) Nuevos derivados de pirimidona con actividad antifungica.
NO172537C (no) Analogifremgangsmaate til fremstilling av terapeutisk aktive 3-desmetyl-4-fluor-mevalonsyrederivater
NO167028C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive pyrazolo(3,4-d)pyrimidinderivater
NO984651L (no) Anvendelse av benzonaftalenderivater for fremstilling av medikamenter for behandling av sykdommer i sentralnervesystemet
NO913644D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive aminosyrederivater.
PT1025101E (pt) Derivados de nafto-imidazo¬1,2-a|piridina sua preparacao e uso no tratamento de perturbacoes do sistema nervoso central
NO900972L (no) Fremgangsmaate for fremstilling av terapeutisk aktive naftalen-derivater.
NO165544C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktivt 2,3-dihydro-1-(8-methyl-1,2,4-triazolo-(4,3-b)pyridazin-6-yl)-4(1h)-pyridinon.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application